Sign in

You're signed outSign in or to get full access.

KB

KALA BIO, Inc. (KALA)·Q3 2024 Earnings Summary

Executive Summary

  • Q3 2024 marked steady operational execution with ongoing enrollment in the Phase 2b CHASE trial of KPI-012 for PCED and expansion into Latin America; topline data timing shifted from Q1 2025 to Q2 2025, a modest schedule delay that is the dominant stock narrative catalyst .
  • Liquidity remained solid with cash and cash equivalents of $49.2M and runway guided into Q4 2025, supported by $3.2M from the CIRM award in August and $1.946M of grant income in the quarter .
  • Expenses were controlled year over year (G&A down to $4.4M vs $5.0M; R&D at $5.2M vs $5.6M), but operating loss widened to $10.0M and net loss was $8.950M (EPS –$1.93), with sequential EPS improvement vs Q2 (–$3.16) .
  • No earnings call transcript was available in filings or the company’s investor materials; communications were via press release and 8‑K .

What Went Well and What Went Wrong

What Went Well

  • Expansion of clinical footprint: Five CHASE trial sites initiated in Argentina with additional Latin American sites in process (subject to regulatory clearance), broadening patient access and potential enrollment pace .
  • Expense discipline: Year-over-year reductions in G&A (–$0.6M) and R&D (–$0.4M) driven by lower stock-based compensation/employee‑related costs and timing of manufacturing for KPI‑012 .
  • Management conviction: “We believe KPI‑012 has the potential to be a first‑in‑class treatment for PCED... and provide a treatment option for a broad population of PCED patients,” signaling confidence in the pivotal pathway if Phase 2b succeeds .

What Went Wrong

  • Schedule slip: Topline CHASE readout moved from Q1 2025 to Q2 2025, introducing a longer catalyst window and potential timeline risk; this was the primary negative surprise for near‑term event timing .
  • Operating performance: Operating loss increased Y/Y to $10.0M from $8.762M, and loss on contingent consideration remeasurement swung to a $0.420M loss vs a $1.744M gain Y/Y, worsening reported OI&E dynamics .
  • Balance sheet mix: A sizable current portion of long‑term debt ($17.977M) underscores near‑term obligations despite adequate liquidity, a watch item given Nasdaq listing covenants referenced in forward‑looking disclosures .

Financial Results

Quarterly P&L Comparison (In thousands unless noted)

MetricQ1 2024Q2 2024Q3 2024
General & Administrative ($USD Thousands)$5,422 $4,317 $4,400
Research & Development ($USD Thousands)$6,351 $5,317 $5,168
Loss on FV Remeasurement of Contingent Consideration ($USD Thousands)$158 $(29) $420
Loss from Operations ($USD Thousands)$(11,931) $(9,605) $(9,988)
Interest Income ($USD Thousands)$504 $504 $570
Interest Expense ($USD Thousands)$(1,455) $(1,458) $(1,478)
Grant Income ($USD Thousands)$1,075 $980 $1,946
Net Loss ($USD Thousands)$(11,807) $(9,579) $(8,950)
Net Loss per Share ($)$(4.20) $(3.16) $(1.93)
Weighted Avg Shares (Basic & Diluted)2,813,210 3,030,213 4,627,578

Notes:

  • Company is clinical-stage and pre-revenue; margins are not applicable given no reported revenue lines in the financial tables .

Balance Sheet Snapshot (Quarter-End; In thousands)

MetricDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024
Cash and Cash Equivalents$50,895 $48,478 $54,197 $49,202
Total Assets$55,949 $53,033 $61,606 $54,079
Working Capital$44,524 $38,208 $39,663 $27,412
Long‑Term Debt, Net of Discounts$34,190 $28,510 $22,832 $17,162
Other Long‑Term Liabilities$5,909 $5,983 $5,867 $6,191
Total Stockholders’ Equity$7,504 $6,661 $13,717 $6,859

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
KPI‑012 CHASE Phase 2b Topline Data TimingReadout WindowQ1 2025 (guided in Q2 release) Q2 2025 (guided in Q3 release) Lowered (timing delayed by ~1 quarter)
Clinical Sites/GeographyOngoingU.S. and existing sites (no LATAM detail) Five sites in Argentina; additional LATAM sites in process (subject to clearance) Raised (site/geography expansion)
Cash RunwayFunding HorizonInto Q3 2025 (Q1 guidance) Into Q4 2025 (Q2 and maintained in Q3) Raised in Q2; Maintained in Q3
CIRM Award SupportFunding ExpectationAnticipated funding (Q1) $3.2M received in Aug; additional funding anticipated Raised (funds received; ongoing expectation)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2)Current Period (Q3)Trend
R&D Execution (KPI‑012 in PCED)Ongoing CHASE enrollment; topline targeted by year‑end (Q1) → shifted to Q1 2025 (Q2) Ongoing enrollment; topline now Q2 2025 Slight schedule slippage; continued execution
Regulatory/Registration PathPotential for CHASE Phase 2b to serve as 1 of 2 pivotal trials (Q1/Q2) Same positioning; contingent on positive results Maintained
Pipeline Expansion (LSCD; KPI‑014 retinal)Exploration of LSCD and KPI‑014 retinal programs initiated (Q1/Q2) Continued exploration; preclinical KPIs reiterated Maintained/Advancing preclinical
Funding & RunwayRunway into Q3 2025 (Q1); into Q4 2025 with private placement/CIRM (Q2) Maintained runway into Q4 2025; $1.946M grant income in Q3 Stable funding profile
Geographic/Operational ScaleU.S. focus; enrollment ongoing (Q1/Q2) Argentina sites initiated; LATAM expansion subject to clearance Expanded footprint

Management Commentary

  • “We remain focused on advancing patient enrollment in our Phase 2b CHASE trial evaluating KPI‑012 for the treatment of PCED and are targeting topline results in the second quarter of 2025.” — Mark Iwicki, Chair & CEO .
  • “We believe KPI‑012 has the potential to be a first‑in‑class treatment for PCED... If successful, this trial may serve as the first of two pivotal trials in support of a BLA submission...” — Mark Iwicki .
  • Cash and runway commentary: “Based on its current plans, KALA anticipates that its cash resources as of September 30, 2024, and anticipated additional funding under the CIRM award, will enable it to fund operations into the fourth quarter of 2025.” .

Q&A Highlights

  • No public earnings call transcript was identified in SEC filings or the company’s investor relations news releases for Q3 2024; disclosures were provided via press release and 8‑K .

Estimates Context

  • We attempted to retrieve S&P Global consensus for Q3 2024 EPS and revenue, but the data was unavailable due to system limits. As a result, estimate comparisons are not included. Values would normally be retrieved from S&P Global.*

Key Takeaways for Investors

  • The primary near‑term catalyst is the KPI‑012 CHASE Phase 2b topline, now expected in Q2 2025; the one‑quarter delay is the dominant narrative driver and should be incorporated into event‑driven positioning .
  • Liquidity is adequate (cash $49.2M) with runway guided into Q4 2025, aided by CIRM funding and steady grant income; balance sheet watch items include the current portion of long‑term debt ($17.977M) .
  • Sequential EPS improved (–$1.93 vs –$3.16), supported by lower G&A and R&D vs Q2; however, operating loss ticked higher Y/Y and contingent consideration remeasurement was a headwind vs Y/Y .
  • Geographic expansion into Argentina and planned LATAM sites could accelerate enrollment and diversify trial operations, potentially de‑risking patient acquisition .
  • With no revenue and pre‑commercial status, valuation and stock moves will be highly sensitive to trial execution updates, regulatory interactions, and runway extension/funding signals .
  • Forward‑looking risk disclosures flagged Nasdaq listing covenants and financing needs as ongoing considerations; monitor compliance and capital markets access ahead of the topline readout .
  • Near‑term trading implication: sentiment likely hinges on any enrollment updates and whether the Q2 2025 timing holds; medium‑term thesis depends on CHASE efficacy and the BLA‑enabling pathway articulated by management .